Microbiotica

Executive Summary

Microbiotica is a clinical-stage biopharmaceutical company specializing in precision live biotherapeutic products (LBPs) for immuno-oncology and inflammatory bowel disease. Founded in 2016 and based in Cambridge, UK, the company leverages a proprietary microbiome discovery platform to identify specific bacterial strains associated with clinical outcomes. Its lead candidate targets enhancement of checkpoint inhibitor efficacy in solid tumors, while an IBD program aims to restore gut homeostasis. As a Phase 1 company, Microbiotica faces typical clinical development risks but benefits from a platform approach that could enable multiple product candidates. Key upcoming milestones include initial clinical data readouts and regulatory filings, which will be critical for validating its technology and securing partnerships. The company's focus on defined bacterial consortia differentiates it in the microbiome space, though early-stage results remain uncertain. With a solid scientific foundation and a clear unmet need, Microbiotica is positioned for potential value creation if its candidates demonstrate safety and efficacy in ongoing trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for lead immuno-oncology candidate30% success
• Q2 2026Regulatory approval (IND/CTA) for IBD candidate80% success